Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of QLS1510 in Healthy Adult Participants
NCT07760077Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2026
- Primary completion
- Jan 2027
01
Overview
Phase 1, randomised, double-blind trial of QLS1510 in inflammatory bowel disease (IBD) (4 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Treatment-Emergent Adverse Events. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
QLS1510
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07760077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07760077.